SCHEMBL698805

SCHEMBL698805

NC(=O)c1cccc(O)c1C(N)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.64
ALDH1A1 P00352 4/20 0.64
HPGD P15428 3/20 0.64
MAPT P10636 1/20 0.64
TSHR P16473 1/20 0.64
HSD17B10 Q99714 1/20 0.64
CA1 P00915 6/20 0.50
CA9 Q16790 6/20 0.50
CA12 O43570 5/20 0.50
CA2 P00918 5/20 0.50
CA7 P43166 5/20 0.50
CA14 Q9ULX7 5/20 0.50
THRB P10828 1/20 0.48
G6PD P11413 1/20 0.47
CASP7 P55210 1/20 0.47
CASP6 P55212 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2343686 0.87 G6PD (0.59) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL3908229 0.87 CA12 (0.64) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL1668962 0.85 CA2 (0.59) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL466296 0.85 KDM4E (0.54) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL10495289 0.85 KDM4E (0.57) KDM4EALDH1A1HPGDMAPTTSHR
Ammonia Solution, Strong SCHEMBL28098266 0.85 CA12 (0.61) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL3453140 0.84 KDM4E (0.61) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL29612815 0.82 MAPT (0.59) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL402013 0.81 BCAT2 (0.56) KDM4EALDH1A1HPGDMAPTTSHR
SCHEMBL4186368 0.81 CA1 (0.66) KDM4EALDH1A1HPGDMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021439-B2 Food or beverage containers coated with polymers of di(amido(alkyl)phenol) compounds SWIMC LLC (US) 2021-06-01 US claimed
US-20090181302-A1 ELECTROLYTE ADDITIVE FOR PERFORMANCE STABILITY OF BATTERIES MEDTRONIC, INC. (US) 2009-07-16 US claimed
WO-2006134469-A1 METHODS OF PREPARING MEK INHIBITOR WARNER-LAMBERT COMPANY LLC (US) 2006-12-21 WO claimed
JP-6157242-A None JP disclosed
US-20240228480-A1 PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS CURIA GLOBAL, INC. 2024-07-11 US disclosed
WO-2024064245-A1 PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 MERCK SHARP & DOHME LLC (US) 2024-03-28 WO disclosed
WO-2024050440-A2 PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED DEEP-TUMOR PENETRATION OF POLYMER NANODRUGS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-07 WO disclosed
WO-2024015106-A1 PEPTIDES FOR TREATMENT OF MEDICAL DISORDERS HUMANWELL PHARMACUETICAL US (US) 2024-01-18 WO disclosed
EP-4281069-A1 PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS NFlection Therapeutics, Inc. (US) 2023-11-29 EP disclosed
CN-113793646-B Spectral image unmixing method based on weighted non-negative matrix factorization and application thereof 上海交通大学 2023-11-28 CN disclosed
CN-117136056-A Process for preparing pyrrolopyridine-anilines 恩福莱克逊治疗有限公司 2023-11-28 CN disclosed
WO-2008063721-A2 LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-29 WO disclosed
WO-2007133976-A2 PROCESS FOR THE PRODUCTION OF AROMATIC CARBOXYLIC ACIDS IN WATER BP CORPORATION NORTH AMERICA INC (US) 2007-11-22 WO disclosed
WO-2007126764-A2 CHEMICALLY MODIFIED VIRAL CAPSIDS AS TARGETED DELIVERY VECTORS FOR DIAGNOSTIC AND THERAPEUTIC AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-11-08 WO disclosed
EP-1830858-A2 3, 6-BICYCLOLIDES Enanta Pharmaceuticals, Inc. (US) 2007-09-12 EP disclosed
WO-2006134469-A1 METHODS OF PREPARING MEK INHIBITOR WARNER-LAMBERT COMPANY LLC (US) 2006-12-21 WO disclosed
WO-2006063039-A2 3, 6-BICYCLOLIDES ENANTA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed
EP-0942918-A2 STEREOSELECTIVE SYNTHESIS OF 24-HYDROXYLATED COMPOUNDS USEFUL FOR THE PREPARATION OF AMINOSTEROLS, VITAMIN D ANALOGS, AND OTHER COMPOUNDS MAGAININ PHARMACEUTICALS INC. (US) 1999-09-22 EP disclosed
WO-1998024800-A2 STEREOSELECTIVE SYNTHESIS OF 24-HYDROXYLATED COMPOUNDS USEFUL FOR THE PREPARATION OF AMINOSTEROLS, VITAMIN D ANALOGS, AND OTHER COMPOUNDS MAGAININ PHARMACEUTICALS INC. (US) 1998-06-11 WO disclosed
JP-H06157242-A SEBUM-INHIBITING AGENT SHISEIDO CO LTD 1994-06-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228480-A1 PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS ADH1C, SIK1, PKN2 KDM4E 71/4885ALDH1A1 150/4885HPGD 3121/4885
US-11021439-B2 Food or beverage containers coated with polymers of di(amido(alkyl)phenol) compounds PAM, AADAC, ACMSD KDM4E 1348/4885ALDH1A1 2009/4885HPGD 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.